0001193125-26-127557
SEC filingSBC Medical Group Holdings Incorporated reported FY 2025 net revenues of $173.6M, a 15.48% decrease from $205.4M in FY 2024. Despite the revenue decline, net income attributable to the company increased 9.38% to $51.0M, driven by a significant reduction in operating expenses (down 30.26% to $59.8M) and a $14.6M gain from other income, primarily from the redemption of life insurance policies. Gross profit was $127.3M with a gross margin of 73.32%. The company generated $24.7M in operating cash flow and ended the year with $163.8M in cash and cash equivalents. Key developments include a strategic $20M equity investment in OrangeTwist, an additional $20M share repurchase authorization, and the identification of continuing material weaknesses in internal controls over related party transactions and executive compensation.
SBC Medical Group Holdings Incorporated reported FY 2025 net revenues of $173.6M, a decrease of $31.8M (15.48%) from $205.4M in FY 2024. Despite the revenue decline, net income attributable to the company increased to $51.0M, up $4.4M (9.33%) from $46.6M in the prior year. This profitability improvement was driven by a significant reduction in operating expenses, which decreased by $25.9M (30.26%) to $59.8M, and a substantial increase in other income, which rose by $11.4M (362.52%) to $14.6M. The company's gross profit was $127.3M with a gross margin of 73.32%, compared to $156.1M and 75.97% in FY 2024. Operating income was $67.5M, representing a 38.87% operating margin.
Revenue declined across most segments, with franchising revenue decreasing 24.72% to $45.9M and management services revenue falling 44.22% to $29.6M. These decreases were primarily due to the revision of the fee structure for determining service fees for each clinic based on size, scale, and performance, effective April 1, 2025, and the discontinuation of clinic operation staff supporting services. Procurement revenue increased slightly by 2.26% to $56.1M, while rental services revenue showed strong growth of 42.69% to $23.0M, driven by new clinic openings and increased demand for medical equipment. Other revenue decreased 6.71% to $18.9M. The appreciation of the Japanese Yen against the U.S. dollar had a favorable impact of $2.1M on net revenues.
The gross margin decreased from 75.97% in FY 2024 to 73.32% in FY 2025, primarily due to decreases in franchising and management services revenue, which have relatively high gross margins. Operating expenses decreased significantly by 30.26% to $59.8M, mainly due to the absence of impairment loss on intangible assets ($15.1M in FY 2024) and stock-based compensation ($13.0M in FY 2024), partially offset by an increase in consulting and professional service fees. The operating margin improved to 38.87% from 34.23% in the prior year. Other income increased substantially to $14.6M, primarily due to a gain on redemption of life insurance policies of $8.7M. The effective tax rate was 37.80% for FY 2025, compared to 36.44% for FY 2024.
Net cash provided by operating activities was $24.7M, derived from net income of $51.0M, adjusted for non-cash items including a gain on redemption of life insurance policies of $8.7M and deferred income tax expense of $5.3M. Net cash used in investing activities was $21.0M, primarily for equity method investments of $20.0M and acquisition of subsidiaries of $22.9M, partially offset by proceeds from redemption of life insurance policies of $17.7M. Net cash provided by financing activities was $38.3M, mainly from borrowings of $34.8M. The company ended FY 2025 with $163.8M in cash and cash equivalents, total assets of $380.4M, total liabilities of $117.1M, and stockholders' equity of $263.3M. Working capital was $170.1M.
The company believes its current cash and cash equivalents from operations and borrowings will be sufficient to meet working capital needs for the next 12 months. It plans to deploy capital for investment opportunities aligned with its growth strategy in the global medical aesthetics market and continues to evaluate dividends and share repurchases. Recent developments include a strategic $20M minority equity investment in OrangeTwist, an additional $20M share repurchase authorization, and the completion of a tender offer for Waqoo, Inc. shares. The company identified continuing material weaknesses in internal control over financial reporting related to oversight of related party transactions and executive compensation, which management is committed to remediating.